1. Home
  2. SANA vs TNDM Comparison

SANA vs TNDM Comparison

Compare SANA & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sana Biotechnology Inc.

SANA

Sana Biotechnology Inc.

HOLD

Current Price

$3.29

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Tandem Diabetes Care Inc.

TNDM

Tandem Diabetes Care Inc.

HOLD

Current Price

$19.32

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SANA
TNDM
Founded
2018
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
SANA
TNDM
Price
$3.29
$19.32
Analyst Decision
Strong Buy
Buy
Analyst Count
5
19
Target Price
$7.80
$28.00
AVG Volume (30 Days)
3.1M
1.4M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
17.24
N/A
EPS
N/A
N/A
Revenue
N/A
$1,014,736,000.00
Revenue This Year
N/A
$8.11
Revenue Next Year
N/A
$11.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.93
52 Week Low
$1.67
$10.00
52 Week High
$6.55
$29.65

Technical Indicators

Market Signals
Indicator
SANA
TNDM
Relative Strength Index (RSI) 47.67 44.91
Support Level $2.84 $17.90
Resistance Level $3.43 $21.68
Average True Range (ATR) 0.29 1.16
MACD -0.01 -0.05
Stochastic Oscillator 24.15 40.23

Price Performance

Historical Comparison
SANA
TNDM

About SANA Sana Biotechnology Inc.

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.

About TNDM Tandem Diabetes Care Inc.

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Share on Social Networks: